NeoGenomics, Inc. (NASDAQ:NEO) Given Average Rating of “Hold” by Analysts

Shares of NeoGenomics, Inc. (NASDAQ:NEO) have been assigned a consensus recommendation of “Hold” from the sixteen brokerages that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $12.5556.

NEO has been the subject of a number of analyst reports. Needham & Company LLC upped their price objective on shares of NeoGenomics from $8.00 to $14.00 and gave the stock a “buy” rating in a research report on Friday, August 29th. Morgan Stanley set a $8.00 price objective on shares of NeoGenomics and gave the stock an “equal weight” rating in a research report on Wednesday, July 30th. William Blair restated a “market perform” rating on shares of NeoGenomics in a research report on Tuesday, July 29th. BTIG Research restated a “neutral” rating on shares of NeoGenomics in a research report on Wednesday, July 30th. Finally, Stephens upped their price objective on shares of NeoGenomics from $6.50 to $11.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 2nd.

NeoGenomics Stock Down 4.8%

NEO stock opened at $10.16 on Tuesday. The company has a fifty day moving average price of $8.47 and a 200 day moving average price of $7.77. NeoGenomics has a 12 month low of $4.72 and a 12 month high of $19.11. The company has a market cap of $1.31 billion, a price-to-earnings ratio of -12.54 and a beta of 1.61. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.92 and a quick ratio of 3.58.

Hedge Funds Weigh In On NeoGenomics

A number of large investors have recently made changes to their positions in the stock. Moody National Bank Trust Division boosted its holdings in NeoGenomics by 1.4% in the third quarter. Moody National Bank Trust Division now owns 90,476 shares of the medical research company’s stock worth $698,000 after purchasing an additional 1,227 shares during the period. CWM LLC boosted its holdings in NeoGenomics by 42.6% in the first quarter. CWM LLC now owns 6,299 shares of the medical research company’s stock worth $60,000 after purchasing an additional 1,883 shares during the period. Moors & Cabot Inc. boosted its holdings in NeoGenomics by 20.0% in the second quarter. Moors & Cabot Inc. now owns 12,000 shares of the medical research company’s stock worth $88,000 after purchasing an additional 2,000 shares during the period. State of Tennessee Department of Treasury boosted its holdings in NeoGenomics by 3.6% in the second quarter. State of Tennessee Department of Treasury now owns 58,082 shares of the medical research company’s stock worth $425,000 after purchasing an additional 2,039 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its holdings in NeoGenomics by 3.6% in the second quarter. The Manufacturers Life Insurance Company now owns 65,004 shares of the medical research company’s stock worth $475,000 after purchasing an additional 2,238 shares during the period. Hedge funds and other institutional investors own 98.50% of the company’s stock.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.